PT  - JOURNAL ARTICLE
AU  - Mosley, Mary
ED  - Pfeffer, Marc A.
TI  - TOPCAT: Effects of Spironolactone on CV Outcomes in Patients with Heart Failure with Preserved Ejection Fraction
DP  - 2013  01
TA  - MD Conference Express
PG  - 16--17
VI  - 13
IP  - 20
4099  - http://mdc.sagepub.com/content/13/20/16.short
4100  - http://mdc.sagepub.com/content/13/20/16.full
AB  - In adults with heart failure and preserved ejection fraction, the mineralocorticoid receptor antagonist spironolactone did not significantly reduce the composite primary outcome of cardiovascular mortality, aborted cardiac arrest, or hospitalization for heart failure (HF) compared with placebo, but it did reduce HF hospitalizations. This article presents the results of the Treatment of Preserved Cardiac Function With an Aldosterone Antagonist [TOPCAT; NCT00094302] study.